Welcome to our dedicated page for Alector SEC filings (Ticker: ALEC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Alector, Inc. (NASDAQ: ALEC) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, sourced in real time from the U.S. Securities and Exchange Commission’s EDGAR system. Alector is a late-stage clinical biotechnology company focused on neurodegenerative diseases, and its filings offer detailed insight into clinical progress, financial performance, and corporate actions.
Investors can review Alector’s Form 8-K filings for material events such as quarterly financial results, restructuring plans, and leadership changes. For example, 8-K reports describe the announcement of second and third quarter financial results, the Phase 3 INFRONT-3 trial outcome for latozinemab (AL001) in FTD-GRN and the associated reduction in workforce, and the appointment of Neil Berkley as Chief Financial Officer while he continues as Chief Business Officer. These filings also outline estimated restructuring charges and separation arrangements for departing executives.
Beyond current reports, users can access periodic filings such as Forms 10-K and 10-Q (when available) to examine Alector’s collaboration revenue, research and development and general and administrative expenses, net loss, and cash, cash equivalents, and investment balances. For a company developing late-stage and preclinical programs in neurodegeneration, these documents are key to understanding funding runway, partnering structures, and portfolio priorities.
Stock Titan enhances these filings with AI-powered summaries that highlight the most important points in lengthy documents, helping readers quickly grasp the implications of complex disclosures. The platform also makes it easier to track insider transaction reports on Form 4 and other ownership-related filings, so users can monitor how executives and major holders interact with ALEC shares. Use this page to navigate Alector’s regulatory history, from clinical trial updates to financial and governance events, with AI tools that streamline document review.
Alector, Inc. entered into a new Sales Agreement with TD Securities (USA) LLC that allows it to offer and sell up to $125,000,000 of common stock through an at-the-market program under its effective shelf registration.
Shares may be sold from time to time on The Nasdaq Global Select Market or through other permitted methods, with Alector setting parameters such as timing, share amounts, daily limits, and minimum prices. TD Cowen may receive up to 3.0% of the gross sales price as compensation. Alector plans to use any net proceeds for general corporate purposes, including research, development and manufacturing of product candidates, working capital, capital expenditures, other corporate expenses, and potential acquisitions or strategic transactions.
Alector, Inc. is offering up to $125,000,000 of common stock through a sales agreement with TD Securities (USA) LLC ("TD Cowen") in an at‑the‑market offering under the company’s shelf registration. Sales may occur from time to time in negotiated transactions, block trades, or on Nasdaq, with TD Cowen acting as agent or principal and receiving up to 3.0% of gross proceeds. The offering assumes a reference price of $2.57 per share (last reported sale price on May 6, 2026), and the as‑adjusted net tangible book value would be $0.83 per share after giving effect to the full $125,000,000 issuance based on 111,025,187 shares outstanding as of March 31, 2026. Use of proceeds is for general corporate purposes, including R&D, manufacturing, working capital, capital expenditures, and potential strategic transactions. Sales under the agreement are at our discretion and may dilute existing and new investors; the sales agent is not required to sell any specific amount.
Alector, Inc. reported a Q1 2026 net loss of $22.9 million, an improvement from $40.5 million a year earlier as it sharply reduced operating expenses. Collaboration revenue from its GSK partnership declined to $1.0 million from $3.7 million, mainly due to lower manufacturing activity.
Research and development expense fell to $17.9 million and general and administrative expense to $8.1 million, reflecting 2025 workforce reductions and program wind-downs. Cash, cash equivalents, and marketable securities totaled $206.5 million, which the company believes will fund operations at least through 2027.
Alector is pivoting toward its ABC blood–brain barrier platform, advancing preclinical programs such as AL037/AL137 for Alzheimer’s disease, AL050 for Parkinson’s and Lewy body dementia, and an siRNA pipeline. In April 2026, GSK discontinued the Phase 2 PROGRESS-AD trial of nivisnebart after a futility analysis.
Alector, Inc. reported first quarter 2026 results and outlined a strategic shift toward its Alector Brain Carrier (ABC) platform after ending a key Alzheimer’s trial. Collaboration revenue was $1.0 million versus $3.7 million a year earlier as work supporting the nivisnebart Phase 2 study wound down.
Research and development expenses fell to $17.9 million from $33.6 million, and general and administrative expenses declined to $8.1 million from $14.7 million, reflecting prior reductions in force. Net loss narrowed to $22.9 million, or $0.21 per share, compared with $40.5 million, or $0.41 per share, in 2025.
Cash, cash equivalents, and investments totaled $206.5 million as of March 31, 2026, which management expects will fund operations at least through 2027. The company is advancing multiple ABC-enabled preclinical programs in Alzheimer’s and Parkinson’s disease while the global Phase 2 PROGRESS-AD trial of nivisnebart was discontinued after a pre-specified interim futility analysis.
Alector, Inc. is asking stockholders to vote at its 2026 virtual annual meeting on June 17, 2026. Holders of 111,025,187 shares of common stock outstanding as of April 20, 2026 are entitled to one vote per share.
Investors will elect three Class II directors to serve until 2029, ratify Ernst & Young LLP as independent auditor for 2026, and cast an advisory “say‑on‑pay” vote on executive compensation. The company describes its board structure, director independence, committee responsibilities, and an outside director pay program that combines cash retainers with stock options and RSUs.
Alector, Inc. Schedule 13G filed by BlackRock, Inc. reports beneficial ownership of 5,784,214 shares of common stock as of 03/31/2026, representing 5.2% of the class. The filing shows sole voting power of 5,697,278 shares and sole dispositive power of 5,784,214 shares. The form is signed by Spencer Fleming on 04/27/2026.
Alector, Inc. principal accounting officer Grace Wong-Sarad reported an open-market sale of 1,820 shares of common stock at $2.65 per share. The trade was executed under a pre-arranged Rule 10b5-1 Trading Plan. After the sale, she continues to hold 104,645 shares directly.
ALEC filing a Form 144 reporting proposed and recent sales of Common Stock by an affiliate. The notice lists restricted shares issued on 06/01/2025 (1,489 shares) and 03/01/2025 (331 shares), and multiple completed dispositions by Grace Wong-Sarad in Feb–Mar 2026, including 8,071 shares on 03/02/2026 and 3,367 shares on 03/03/2026.